1. The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
   Qianning Zhang et al, 2022, Frontiers in Oncology CrossRef
2. PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach
   Antonella Fameli et al, 2022, Frontiers in Oncology CrossRef
3. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
   A Daban et al, 2023, OncoImmunology CrossRef
4. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
   Iñigo Les et al, 2022, Frontiers in Pharmacology CrossRef
5. The presence of autoantibodies is associated with improved overall survival in lung cancer patients
   Keying Jing et al, 2023, Frontiers in Oncology CrossRef
6. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
   Hui Tang et al, 2022, Frontiers in Immunology CrossRef
7. Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort
   Fulvia Ceccarelli et al, 2024, Clinical and Experimental Medicine CrossRef
8. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review
   Ariadna Juarez-Garcia et al, 2022, Lung Cancer CrossRef
9. Role of B cells in immune‐related adverse events following checkpoint blockade
   Kavita M. Dhodapkar et al, 2023, Immunological Reviews CrossRef
10. B cell clonality in cancer
    E.A. Bryushkova et al, 2024, Seminars in Immunology CrossRef
11. Circulating predictive markers of immune checkpoint inhibitors in non-small cell lung cancer
    A. A. Musaelyan et al, 2021, Advances in Molecular Oncology CrossRef
12. 免疫チェックポイント阻害剤を使用した際の肝機能障害の特徴
    , 2020, Kanzo CrossRef
13. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
    Atsuto Mouri et al, 2021, Frontiers in Oncology CrossRef
14. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade
    Valerio Nardone et al, 2021, Frontiers in Oncology CrossRef
15. Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
    Sehrish Qureshi et al, 2023, Frontiers in Nephrology CrossRef